Th e maintenance of the body weight at a stable level is a major determinant in keeping the higher animals and mammals survive. Th e body weight depends on the balance between the energy intake and energy expenditure. Increased food intake over the energy expenditure of prolonged time period results in an obesity. Th e obesity has become an important worldwide health problem, even at low levels. Th e obesity has an evil eff ect on the health and is associated with a shorter life expectancy. A complex of central and peripheral physiological signals is involved in the control of the food intake. Centrally, the food intake is controlled by the hypothalamus, the brainstem, and endocannabinoids and peripherally by the satiety and adiposity signals. Comprehension of the signals that control food intake and energy balance may open a new therapeutic approaches directed against the obesity and its associated complications, as is the insulin resistance and others. In conclusion, the present review summarizes the current knowledge about the complex system of the peripheral and central regulatory mechanisms of food intake and their potential therapeutic implications in the treatment of obesity. Th e maintenance of the body weight at a stable level is a major determinant in keeping the higher animals and mammals survive (Jequier and Tappy 1999). As a compensatory mechanism, hunger increases and energy expenditure decreases the weight loss. However, opposite responses are triggered when body weight increases. Body weight can change only when energy intake is not equal to energy expenditure over a given period of time (Bray et al. 2012) . A complex physiological control system is involved in the maintenance of the energy balance. Th is system includes aff erent signals from the periphery about the state of the energy stores and eff erent signals that affect the energy intake and expenditure (Sandoval et al. 2008) . Th is regulatory system is formed by multiple interactions between the gastrointestinal tract (GIT), adipose tissue, and the central nervous system (CNS). It is infl uenced by behavioral, sensorial, autonomic, nutritional, and endocrine mechanisms (Boguszewski et al. 2010 ).
Th e maintenance of the body weight at a stable level is a major determinant in keeping the higher animals and mammals survive (Jequier and Tappy 1999) . As a compensatory mechanism, hunger increases and energy expenditure decreases the weight loss. However, opposite responses are triggered when body weight increases. Body weight can change only when energy intake is not equal to energy expenditure over a given period of time (Bray et al. 2012) . A complex physiological control system is involved in the maintenance of the energy balance. Th is system includes aff erent signals from the periphery about the state of the energy stores and eff erent signals that affect the energy intake and expenditure (Sandoval et al. 2008) . Th is regulatory system is formed by multiple interactions between the gastrointestinal tract (GIT), adipose tissue, and the central nervous system (CNS). It is infl uenced by behavioral, sensorial, autonomic, nutritional, and endocrine mechanisms (Boguszewski et al. 2010 ).
Satiety and adiposity signals
Th e food intake control includes a short-term regulation, which determines the beginning and the end of a meal (hunger and satiation) and the interval between the meals (satiety) and a long-term regulation with factors (signals of adiposity), which help to regulate the body energy depots (Cummings and Overduin 2007) .
Th e satiation means a suppression of the hunger and termination of the food intake aft er ingestion of a certain amount of food (Smith 1998) . Th e mechanisms controlling satiation determine the size of the meal. Satiety is a period of time between the meals with no hunger (Strubbe and Woods 2004) . Th is time period is variable and its termination coincides with the refeeling of the hunger accompanied by the consumption of the next meal, thus resuming the cycle of the food intake (Hargrave and Kinzig 2012) (Figure 1) .
Th e mechanisms, which control the size of the meal (satiation) and those controlling the intervals between the meals (satiety), diff er (de Graaf et al. 2004; Benelam 2009) . Th e satiation is determined by physiological and psychological mechanisms, which trigger the aff erent signals to brain from multiple sites in the GIT, including the stomach, the proximal small intestine, the distal small intestine, and the colon (Ritter 2004; Keenan et al. 2015) .
Th e satiety is aff ected by short-term signals from GIT (Zac-Varghese et al. 2010 ) and long-term signals from the body energy store (Woods 2005) . Th e signals from GIT are transmitted primarily via the vagal and spinal nerves to the nucleus of the solitary tract (NTS). Transection of all the gut sensory vagal fi bers has been shown to increase the meal size and its duration (Schwartz 2000; Powley et al. 2005) . However, the stimulation of the vagus nerve did not result in a weight gain (Koren and Holmes 2006) . Th e long-term signals (adiposity signals) reach the arcuate nucleus (ARC) via the median eminence or by crossing the blood-brain barrier (BBB). Th ere exists, however, a large number of integrations and convergences between these signals mediated by neural connections between the ARC nucleus, NTS, and the vagal aff erent fi bers (Boguszewski et al. 2010) .
Th e hypothalamus role in the food intake control
Th e hypothalamus plays a major role in the control of the appetite. In the hypothalamus, aff erent signals from the gut and brain stem relied and eff erent signals for the food intake control are processed. Within the hypothalamus, there are many nuclei and neuronal circuits involved in the food intake regulation, such as the ARC, a key hypothalamic nucleus in the appetite control, the paraventricular nucleus (PVN), the dorsomedial nucleus (DMN), the ventromedial nucleus (VMN), and the lateral hypothalamic area (LHA) (Wynne et al. 2005) .
Arcuate nucleus (ARC) contains two neuronal populations with opposing eff ects on the food intake, i.e. neurons, which stimulate the food intake co-expressing neuropeptide Y (NPY) and agouti related peptide (AgRP), and neurons, which suppress the feeding co-expressing pro-opiomelanocortin (POMC) and cocaine-and amphetamine-regulated transcript (CART). Both types of the neurons project to the hypothalamic areas, which are involved in the control of appetite including the DMN, PVN, and LHA (Suzuki et al. 2010) (Figure 2) .
Neuropeptide Y is the most abundant neurotransmitter in the brain. Th e hypothalamic NPY neuropeptide levels increase during the fasting and decrease aft er the feeding (Wynne et al. 2005) . Th e NPY integrates a large family of peptides that includes peptide YY (PYY) and pancreatic polypeptide (PP), the eff ects of which are mediated via the six G-protein-coupled receptors named Y1 to Y6. Th e orexigenic eff ect of NPY is mediated by stimulation of the hypothalamic Y1R and Y5R, in addition to the local inhibition of the POMC neurons in the ARC. In addition, AgRP acts as a selective antagonist at MC3R and MC4R in the PVN (Suzuki et al. 2010) .
Activation of NPY may explain the easy recovery of weight observed in the obese individuals undergoing treatment, since weight reduction leads to a decrease in the leptin, activation of NPY, and consequently to hyperphagia and reduced energy expenditure (Boguszewski et al. 2010) . Regain of the weight, following the weight loss, can be a result of the modifi ed adipose tissue cellularity, endocrine function, and energy metabolism (Ochner et al. 2013) .
Th e anorexigenic eff ect of POMC has been proven by an increase in the food intake and adiposity as a result of POMC gene mutations in humans (Krude Figure1 . Food intake cycle.
et al. 1998) and gene deletion in canine (Raff an et al. 2016) . In the ARC nucleus, the cleavage of POMC results in the production of melanocortin peptides including adrenocorticotropic hormone (ACTH) and α-melanocyte-stimulating hormone (α-MSH) that exert their eff ects by binding to G-protein coupled melanocortin receptors (MC-Rs). From fi ve, two melanocortin receptors are expressed in the brain, MC4-R and MC3-R. Hyperphagia and obesity result from the targeted deletion of MC4-R in mice (Huszar et al. 1997) . Th e higher fat content that have been noticed in MC3-R knockout mice (Chen et al. 2000) refl ects the importance of these two receptors in controlling the appetite. Th e inhibitory eff ect of the melanocortinergic neurons is antagonized by AgRP at MC4-R and MC3-R (Bagnol et al. 1999) . Th e products of POMC cleavage, the fi ve diff erent subtypes of G-protein-coupled receptors, and the endogenous antagonists, AgRP and Agouti constitute the melanocortin system that is involved in many important physiological processes. In addition to food intake, the melanocortin system is involved in the regulation of pigmentation, adrenocortical steroidogenesis, natriuresis, erection, and exocrine secretion (Cone 2005; Wynne et al. 2005) .
Majority of the neurons that express POMC also co-express CART mRNA. Th e fasting decreases CART expression (Kristensen et al. 1998) . Animal studies have shown a decrease in the food intake upon the intracerebroventricular (ICV) administra- Short and long signals for food intake control. Abbreviations: ARC -arcuate nucleus; NPY/AgRP -neuropeptide Y and agouti related peptide; POMC/CART -pro-opiomelanocortin and cocaine-and amphetamine-regulated transcript; PVN -paraventricular nucleus; LHA -lateral hypothalamic area; DMN -dorsomedial nucleus; VMN -ventromedial hypothalamic nucleus; ME -median eminence; AP -area postrema; GLP-1 -glucagon-like peptide-1; CCK -cholecystokinin; PP -pancreatic polypeptide; PYY -peptide YY; OXM -oxyntomodulin; BBB -blood-brain barrier; MCH -melanin-concentrating hormone; α-MSH -alpha melanocyte stimulating hormone; BDNRF -brain derived neurotrophic factor; CRH -corticotrophin releasing hormone; NTS -nucleus tractus solitaries; DVC -dorsal vagal complex; TRH -thyroid releasing hormone; MC4-R -melanocortin receptor 4; MC3-R -melanocortin receptor 4; Y1R & Y5R -neuropeptide Y receptors 1 & 5 tion of CART (Aja et al. 2001; Rohner-Jeanrenaud et al. 2002) and its increase aft er ICV injection of CART antiserum (Kristensen et al. 1998) . However, recent studies have shown an increase in the food intake after injection of CART into the hypothalamic nuclei in streptozotocin-diabetic rats (Hou et al. 2010) . Th is suggests that CART can be orexigenic or anorexigenic, based on the neural circuit that is stimulated. It has been suggested that decreased expression of CART mRNA in ARC and PVN regions may contribute to the development of high-fat diet-induced obesity in mice. In addition, CART in the DMN and LH may be involved in the activation of the orexigenic eff ect (Yu et al. 2008) .
Neurotensin (NT), a peptide expressed in the brain and GIT, plays a role in the regulation of food intake as evidenced by the inhibition of the food intake following the central and peripheral NT administration (Ratner et al. 2016) . Transient increase in the food intake has been shown following pharmacological NT antagonism in a rat Roux-en-gastric bypass model (Ratner et al. 2016) . It has been shown that peripheral NT administration inhibits the food intake by increasing the POMC mRNA in the ARC (Ratner et al. 2016) . Th e anorexigenic eff ect of NT is mediated by neurotensin receptor-1 (Ntsr1), as it has been evidenced by Kim and Mizuno (2010) . Other peptides that act on Ntsr1 and inhibit food intake include neuromedin U (Kim and Mizuno 2010) and xenin, a peptide that is released from the small intestine (Sterl et al. 2016) .
Th e hypothalamic paraventricular nucleus (PVN) contains several neurons that secrete anorexigenic substances such as corticotropin-releasing hormone (CRH), oxytocin, and thyrotropin-releasing hormone (TRH). Each of these peptides acts to decrease food intake, increase the metabolic rate, or both (Morton et al. 2012; Blevins et al. 2015; Moore et al. 2015) . Th e CRH is a 41 amino acid peptide, which is widely distributed throughout the brain, but is particularly abundant in the medial parvocellular division of the PVN (Sawchenko et al. 1985) . In addition to its role in controlling the activity of the pituitary adrenal axis, CRH controls the food intake too. Within the brain, CRH with its two receptor types, CRH type 1 (CRH1-R) and CRH type 2α (CRH2α-R), its binding protein, and its closely related peptide urocortin, forms a network of neuronal pathways that is capable of interacting with other circuitries controlling the food intake (Mastorakos and Zapanti 2004) . It has been shown that CRH mediates the anorexigenic eff ect of α-MSH in fi sh (Matsuda et al. 2008) and ELABELA in the adult mouse (Santoso et al. 2015) . ELABELA, a novel hormone consisting of 32 amino acid peptides, found in humans and other vertebrates, is considered to play an important role in the circulatory system. It has been shown that ICV injection of ELABELA reduces food intake and activates the arginine vasopressin (AVP) and CRH neurons in the PVN in a dose dependent manner (Santoso et al. 2015) .
A defect in the synthesis and release of the CRH has been implicated in the development of the obesity in laboratory animals (Mastorakos and Zapanti 2004) . Moore et al. (2015) have reported a benefi cial eff ect of CRH1-R antagonism in the attenuation of the stress-induced consumption of palatable diets in female rhesus monkeys. It has been suggested that anorexigenic eff ect of CRH is conferred by CRH1R (Hotta et al. 1999 ). However, it has been observed that CRH is able to decrease the food intake in CRH1R knockout mice as much as in wild type littermates suggesting that both CRH1-R and CRH2-R may mediate the food intake inhibitory eff ect of CRH and urocortin but at diff erent time course (Sekino et al. 2004) .
Oxytocin, a hypothalamic peptide, is released into the circulation through the posterior pituitary and also directly acts on the central nervous receptors. In addition to its role in regulation of reproductive functions, such as mother-infant interaction and lactation, it is a potent modulator of social behaviors including attachment and sexual behavior (MeyerLindenberg et al. 2011) . Moreover, animal studies and pilot experiments in humans have indicated that oxytocin might have a role in the regulation of eating behavior and metabolism in normal weight as well as with diet-induced obesity. Oxytocin administration in animals and humans inhibits food intake, increases energy expenditure, and reduces glucose levels (Morton et al. 2012; Ott et al. 2013; Lawson et al. 2015) . Interestingly, there are experiments, which suggest that the metabolic eff ects of oxytocin may be even enhanced in diet-induced obese in comparison to control weight (Th ienel et al. 2016 ) with absent or minimal side eff ects. Th is makes oxytocin a promising pharmacological intervention in obesity Zhang et al. 2013) . A recent study has shown that central oxytocin acts via an oxytocin receptor that is expressed in the nucleus accumbens core to decrease food intake driven by hunger and reward in rats off ered a meal in a non-social setting (Herisson et al. 2016) .
Galanin-like peptide (GALP) is a neuropeptide expressed in several brain areas including hypothalamic nuclei involved in the appetite regulation such as ARC, PVN, and median eminence (Wodowska and Ciosek 2015) . GALP seems to be a promising peptide in the obesity treating. GALP administration has been eff ective in ameliorating the obesity in mice, where it has been shown that brain uptake of GALP is higher aft er intranasal than intravenous administration Kageyama et al. 2016) . Administration of GALP in mice, but not rats, resulted in an acute orexigenic eff ect that may be explained by an NPY input to GALP neurons from the ARC NPYcontaining neurons and orexin-containing neurons in LHA, in addition to fi bers that project from GALP neurons to orexin and melanin-concentrating hormone (MCH) ones in the LHA (Takenoya et al. 2005 ). However, this orexigenic eff ect was transient and followed by a chronic anorexigenic eff ect and decrease of the body weight. It has been suggested that GALP expression is regulated by leptin and insulin as evidenced by the presence of leptin receptors in more than 85% of GALP neurons . Th e expression of GALP in the brain has been found to be increased aft er administration of the leptin in fasted rats as compared with controls (Lawrence and Fraley 2011) . GALP expression has been found to be restored in diabetic rats aft er insulin administration (Fraley et al. 2004) .
Th e lateral hypothalamic area (LHA). Orexin A and B, a pair of neuropeptides, are produced in cells located in the hypothalamic lateral and perifornical areas. Orexin A has been found to enhance the food intake when injected into certain hypothalamic nuclei such as LHA, PVN, DMN, and the perifornical area. However, orexin B has been found to be ineff ective when injected to any of the hypothalamic nuclei (Dube et al. 1999) . Hypocoretin-1 (HC, Orexin A) is a neuropeptide that is involved in the regulation of many physiological functions, such as sleep, appetite, and arousal. Recently, a study on rats has shown an increase in the food consumption aft er intranasal administration of HC (Dhuria et al. 2016) . In addition to orexin expressing cells, LHA contains MCH expressing cells that extend in a wider area. Th ese two types of cells are targets for NPY and AgRP projections coming from the ARC (Broberger et al. 1998) .
Th e ventromedial nucleus (VMN). In addition to the large population of glucoresponsive neurons in the VMN, the brain-derived neurotrophic factor (BDNF) is also highly expressed. Central infusion of BDNF reduces food intake and induces weight loss in rats (Pelleymounter et al. 1995) . Th e VMN receives NPY, AgRP, and POMC neuronal projections from the ARC and it is thought that POMC neurons from the ARC play a role in activating BDNF neurons in VMN to decrease the food intake (Xu et al. 2003) .
Th e dorsomedial nucleus (DMN) contains a high level of NPY and α-MSH terminals originating in the ARC. From DMN, α-MSH fi bers project to the TRHcontaining neurons in the PVN (Mihaly et al. 2001) . Destruction of the DMN results in hyperphagia and obesity (Bernardis and Bellinger 1986) .
Role of the brainstem
Th e dorsal vagal complex (DVC), located within the brainstem, is a crucial in the interpretation and relaying of peripheral signals from the gut to the hypothalamus. Th e DVC consists of the dorsal motor nucleus of the vagus (DVN), the area postrema (AP), and the NTS within which POMC neurons exist (Schwartz 2010) . Receptors for a variety of hormones controlling food intake have been found to be expressed in the brainstem vagal aff erent neurons including cholecystokinin (CCK) 1R and CCK 2R at which both CCK and gastrin act (Moriarty et al. 1997) , insulin receptors, GLP-1 (Nakagawa et al. 2004 ) and GLP-2R (Nelson et al. 2007 ), growth hormone secretagogue receptor (GHS)-R1 at which ghrelin acts (Date et al. 2002) , the orexin receptor, OX-R1 (Burdyga et al. 2003) , and leptin (Burdyga et al. 2002) .
Role of the reward system
Diff erent brain circuits involved in the reward, as the hippocampus, amygdala, pre-frontal cortex, and midbrain, have been found to be activated by food and food-related cues (Palmiter 2007; Kenny 2011) . Dopamine is a neurotransmitter that is released from the neurons in the mesolimbic system and mediate emotions and pleasure (reviewed by Nutt et al. 2015) . It has been demonstrated that with food intake dopamine release is enhanced in the circuits that mediate the pleasurable aspects of the eating (Volkow et al. 2011 ). However, decreased body weight aft er chronic food deprivation has been shown to be associated with a decrease of dopamine levels (Pothos et al. 1995) . Th is suggests that increased food intake aft er chronic food deprivation and weight loss may represent a compensatory mechanism to restore the baseline dopamine levels .
Th e endogenous opioid and endocannabinoid systems play important role in the reward-related feeding (Pomorska et al. 2016) . Th e endogenous opioid peptides such as β-endorphins derived from POMC, which is a precursor of opioids, bind to opioid receptors that are distributed in the hypothalamic regions controlling the food intake (reviewed by Kenny 2011) .
Some studies have shown that infusions of μ-opioid receptor agonists stimulate feeding behavior in rats, while opioid receptor antagonists infused decrease the consumption of the preferred food without affecting the intake of the less palatable alternatives (reviewed by Goodman 2008). In addition, systemic injection of a μ-opioid antagonist prevents the stimulatory eff ect of palatable food on dopamine release in the nucleus accumbens, which confi rms the excitatory eff ects of opioids on the dopamine system (Tanda and di Chiara 1998).
Role of the endocannabinoid system
Th e plant-derived cannabinoids such as Δ 9 -tetrahydrocannabinol (THC) as well as their synthetic analogues, act in the organism by activating specifi c cell-surface receptors that are normally engaged by a family of endogenous ligands; the endocannabinoids. Th e fi rst endocannabinoid discovered was named anandamide (AEA), the amide of arachidonic acid (AA) and ethanolamine (Et) (Devane et al. 1992) . A second arachidonic-acid derivative is the 2-arachidonoylglycerol (2-AG) that binds to cannabinoid receptors was subsequently described (Mechoulam et al. 1995) .
Endocannabinoids are produced by a variety of cell types including endothelial cells (Gauthier et al. 2005) , adipocytes ), glial cells (Gonthier et al. 2007 ), macrophages (Di Marzo et al. 1999) , and Purkinje cells (Maejima et al. 2001) . Th e endocannabinoid system (ECS) consists of the endogenous cannabinoid ligands, the enzymatic machinery involved in their synthesis uptake and degradation, the G-protein-coupled cannabinoid receptors type 1 and 2 (CB1 and CB2) (Kogan and Mechoulam 2006; Quarta et al. 2011) . CB1 has been found to be widely and abundantly distributed in tissues involved in the energy homeostasis, including the hypothalamus, brainstem, mesolimbic region, and peripheral tissues such as the GIT, fat, liver, muscle, thyroid, and pancreas (Matias et al. 2006) . CB2 is well known in his immune modulatory eff ect (Cabral and Griffi nTh omas 2009). However, recently it has been found that CB2 plays a role in the energy homeostasis and food intake (Verty et al. 2015) (Figure 3) .
Th e ECS is involved in the regulation of food intake and energy balance as evidenced by the following: 1) binding of endocannabinoids to CB1 receptors results in an increased appetite, weight gain, lipogenesis, and lower insulin sensitivity (Horvath 2003) ; 2) an increased food intake aft er central administration of cannabinoids mediated by CB1 activation (Jamshidi and Taylor 2001; Verty et al. 2005 ) and its suppression by blocking the cannabinoid receptor that has been found to have a direct participation of sympathetic nervous system, ghrelin, or leptin (Alen et al. 2013; Silvestri and Di Marzo 2013) ; 3) increased endocannabinoid hypothalamic levels in rodents with diet-induced or genetic obesity (Quarta et al. 2011) . Th e endocannabinoids increase the production of the hypothalamic appetite stimulating transmitters and reduce the production of the appetite-suppressing signals. In the reward center of the mesolimbic region, the endocannabinoids promote the motivation to eat palatable food (Di Marzo and Matias 2005) .
Food intake has been found to be suppressed by genetic deletion or pharmacological CB1 block- ade in the lean and obese starved animals (Verty et al. 2009; Quarta et al. 2010; Quarta et al. 2011; Rorato et al. 2013) . However, other studies have shown that CB1 blockade may result in a food intake independent decrease in fat mass mainly through lipolysis (Jbilo et al. 2005; Nogueiras et al. 2008; Quarta et al. 2010) . As a consequence, CB1 blockade has been shown to be eff ective in ameliorating the obesityrelated metabolic disorders (Cota et al. 2003; Ravinet Trillou et al. 2004; Quarta et al. 2011) .
Th e activation of ECS has been found to promote energy storage (Bermudez-Silva et al. 2010; Quarta et al. 2010; Bermudez-Silva et al. 2012) . Physiologically, ECS is activated in response to stressful stimuli helping the aff ected tissues to restore their steady state (Pagotto et al. 2006 ). Ingestion of food, CCK and other gastric peptides decrease the activity of the ECS. In contrast, increased circulating levels of ghrelin in situations of the food deprivation are associated with higher endocannabinoid activity, suggesting that the orexigenic eff ect of ghrelin occurs, at least in part, by activation of the endocannabinoid system (Boguszewski et al. 2010). Leptin produced from the adipose tissue reduces the levels of endocannabinoids due to interference with 2-AG synthesis and increased anandamide degradation (Di Marzo and Matias 2005) .
Is the over-activity of ECS a cause of obesity? Th e sustained hyperactivity of the ECS could lead to hyperphagia with a progressive and excessive accumulation of fat and subsequent development of obesity (Ravinet Trillou et al. 2004 ), insulin resistance, and disturbed lipid profi le (Foster-Schubert and Cummings 2006) . Obesity has been found to be associated with a dysregulation of the ECS. CB1 has been found to be less in obese and returned to the normal aft er weight loss (Bennetzen et al. 2011 ). Blocking of CB1 in humans using rimonabant, as a treatment for obesity, resulted in psychiatric side effects, which resulted in withdrawal of the drug (Lee et al. 2009 ). However, targeting the peripheral CB1 receptors has been found to safely alleviate the cardio-metabolic disorders associated with the obesity (Tam et al. 2010) .
Th e eff ectiveness of CB1 receptor blockade in decreasing body weight and amelioration of the obesity related metabolic disorders may be mediated by elimination of ECS eff ects on the appetite, increase in adiponectin levels, which is thought to result in increased fat metabolism and an improvement in glucose metabolism (Scheen et al. 2006 ) and increase in the mitochondrial biogenesis in white adipocytes by inducing the expression of nitric oxide (NO) produced by endothelial NO synthase (eNOS), which is linked to the prevention of high-fat diet-induced fat accumulation, without concomitant changes in food intake (Tedesco et al. 2008 ).
Role of the gastrointestinal tract peptides
Th e gastrointestinal (GI) tract is the largest endocrine organ in the body where many hormone genes are expressed and bioactive peptides are produced (Rehfeld 1998). Many of these hormones and peptides are involved in the peripheral control of the food intake by controlling the initiation and termination of the meal. Besides the role of peptides in satiation and satiety, gastric distension has a satiating eff ect that forms the basis of gastric balloon use in humans as a treatment for obesity (Martin et al. 2007) .
Cholecystokinin (CCK) was the fi rst gut hormone shown to modulate the food intake (Bray and York 1972) . CCK is secreted postprandial from I cells of the small intestine into the circulation with a plasma half-life of a few minutes. CCK levels rise rapidly reaching a peak within 15 minutes aft er a meal. It is also reported to reduce food intake in humans and rodents (Liddle et al. 1985) . Th e action of CCK is mediated by two CCK receptor subtypes: CCK1 and CCK2, which are widely distributed in the brain including the brainstem and the hypothalamus (Moran et al. 1998) . Th e anorectic action of CCK has been found to be mostly mediated through CCK1R on vagal aff erents (Moran et al. 1997) . Th ere are various forms of CCK with various eff ects on the meal size and the intervals between meals. While CCK 58 and CCK-8 both stimulate satiation, thereby reducing meal size, CCK-58 consistently exerts a satiety eff ect (Overduin et al. 2014 ). Similar results have been reported with CCK-33, which has been found to reduce the food intake by prolonging the inter-meal interval (Washington et al. 2011; Lateef et al. 2012) .
Peptide tyrosine tyrosine (PYY) is a member of the pancreatic polypeptide (PP) family (Lin et al. 2004) . Th ere are two circulating forms of PYY released by L cells in the distal gut: PYY (1-36) and PYY (3-36). PYY (3-36), the major circulating form, is produced by cleavage of the N-terminal TyrosineProline residues from PYY (1-36) by the enzyme dipeptidyl-peptidase-IV (DPP-IV) (Wynne et al. 2005) . Currently, the DPP-IV inhibitors are being evaluated for their eff ects on the obesity and metabolic traits (Martin et al. 2015) .
PYY (3-36) binds with highest affi nity to the hypothalamic Y2R causing a reduction in food intake. It also binds to other Y receptors, although with much lower affi nity. In addition to PYY's anorectic eff ect on food intake, it also increased the energy expenditure (Boey et al. 2008 ) and delayed gastric emptying in mice (Talsania et al. 2005) . Th e low level of PYY in obese subjects and their blunt increase aft er a meal possibly results in impaired satiety and hence greater food intake (le Roux et al. 2006 ). However, this was not supported by the fi ndings of another study that has shown no diff erences in the levels of PYY between lean and the obese (Pfl uger et al. 2007 ). Weight regain aft er Roux-en-Y gastric bypass (RYGB) has been found to be attributed to the failure to sustain a high level of PYY indicating that combining RYGB with pharmacologic stimulation of PYY secretion in patients aft er RYGB who exhibit inadequate PYY concentration may increase long-term success of surgical weight reduction in morbidly obese adults (Meguid et al. 2008) .
Pancreatic polypeptide (PP) is a hormone released from the pancreas in response to food ingestion. PP plasma levels are reduced by obesity and increased by anorexia nervosa. Th e peripheral administration of PP has been shown to decrease the food intake in rodents and humans Jesudason et al. 2007) . PP is thought to reduce food intake through the following mechanisms 1) stimulation of Y4 and Y5 receptors in the dorsal vagal complex, including the area postrema (AP), the nucleus of the solitary tract (NTS) and the dorsal motor nucleus of the vagus (DMV) (Whitcomb et al. 1997; Lin et al. 2009 ); 2) sending anorexigenic signals via the brainstem and hypothalamic neuropeptides (Hankir et al. 2011) ; 3) modulation of the expression of other peripheral peptides such as ghrelin, and 4) delay in gastric emptying that seemed to occur only in animal models and not in humans. Th e anorectic eff ects of PP and PYY (3-36) are abolished in abdominal vagotomised rats, suggesting that PP and PYY (3-36) induce anorexia via vagal aff erent nerves (Iwasaki et al. 2013) .
Enterostatin and apolipoprotein A-IV. Enterostatin is a peptide secreted from the exocrine pancreas in response to fat intake to facilitate its digestion (Cummings and Overduin 2007) . Both peripheral and central enterostatin administrations have been found to decrease dietary fat intake in animals, conversely enterostatin-receptor antagonists have been found to do the opposite (Okada et al. 1992) . Apolipoprotein A-IV (APO AIV) is a glycoprotein secreted from the intestine in response to fat absorption and chylomicron formation to be used in packaging of digested lipids in transit through lymphatic to blood. It has been hypothesized that APO AIV represents a link between the short-and long-term regulations of lipid-related energy balance (Qin and Tso 2005) based on the following fi ndings: 1) APO AIV is produced in the hypothalamic arcuate nucleus (Tso et al. 2004) and 2) exogenous administration of APO AIV has been found to decrease meal size, food intake, and weight gain in rats, whereas APO AIV-specifi c antibodies have been found do the opposite (Fujimoto et al. 1993) .
Glucagon-like peptide-1 (GLP-1). Th e pro-glucagon gene is cleaved into diff erent products by the enzymes convertase 1 and convertase 2, a process that varies among the tissues. In the pancreas, the main product of this cleavage is glucagon, whereas in the intestine the GLP-1 and GLP-2. GLP-1 is released into the circulation aft er meals, physiologically acting as an incretin that promotes increased pancreatic insulin secretion and consequently infl uences the glucose homeostasis (Holst 2004).
DPP-IV degradation and renal clearance rapidly inactivate and remove GLP-1 from the plasma circulation, resulting in a half-life of 1-2 minutes (Mentlein et al. 1993) . GLP-1 has two biologically active forms, GLP-1 (7-37) amide and GLP-1 (7-36) amide, the latter being the major circulating form in humans. GLP-1R expression is widely distributed particularly in the brain, GIT, and pancreas (Baggio and Drucker 2014) . Circulating GLP-1 levels rise aft er a meal and fall in the fasted state. GLP-1 reduces food intake (Parker et al. 2013) , suppresses glucagon secretion (Hare 2010) , and delays gastric emptying (Little et al. 2006) .
Oxyntomodulin (OXM) is another product of the proglucagon gene, which is released from the intestinal cells into the circulation in proportion to caloric intake (Ghatei et al. 1983) . OXM has been found to reduce the food intake and promote increased energy expenditure resulting in negative energy balance that supports the role of oxyntomodulin as a potential anti-obesity therapy . Th e most likely mechanism of OXM action on energy homeostasis is through its binding to the GLP-1 receptor as GLP-1 receptor antagonists have been found to reduce the food intake (Dakin et al. 2004) . Although OXM binds the GLP-1 receptor with lower affi nity than GLP-1 by approximately 50 fold less strongly than GLP-1, they are equally eff ective in causing anorexia. Th us, diff erences in the biological eff ects of OXM and GLP-1 may be due to variations in the tissue penetration, degradation, or intracellular signaling pathways (Fehmann et al. 1994; Baggio et al. 2004) .
Glucagon is produced by alpha cells of the pancreatic islets. In contrast to GLP-1 and insulin, hypoglycemia causes an increase in the glucagon secretion resulting in hepatic glycogenolysis. Peripheral as well as central administration of glucagon in rats reduced food intake and meal size in addition to reducing body weight gain (Geary et al. 1993; Honda et al. 2007 ). Combination of glucagon and GLP-1 agonists has been found to be benefi cial as a treatment of obesity rodents have been demonstrated (Pocai et al. 2009 ) as GLP-1 prevented the hypoglycemia induced by glucagon (Parker et al. 2013 ).
Insulin and amylin. Insulin, a peptide secreted from beta cells of the pancreas aft er a meal and its amount along with leptin has been found to be directly proportional to white fat (Considine et al. 1996) that may refl ect the important role of both as an adiposity signals from adipose tissue to the hypothalamic centers controlling energy balance. Although there is a controversy in the issue weather insulin can cross the blood brain barrier and weather it is synthesized by the brain itself (Woods et al. 2003; Gerozissis 2004) . It has been found that central administration of insulin caused a decrease in food intake and weight loss in animals (Woods et al. 1979; Riedy et al. 1995) whereas opposite eff ect has been found when insulin antibodies were administered in or near the mediobasal hypothalamus (McGowan et al. 1992) where insulin receptors are highly expressed (Halmos and Suba 2011) .
Amylin is a peptide co-secreted with insulin, inhibits gastric emptying, gastric acid and glucagon secretions, and reduces food intake and meal size in animals (Young and Denaro 1998) . Th e anorectic action of amylin has been found to be mediated by decreasing the expression of orexigenic neuropeptides (Lutz 2009) . Th e eff ect of chronic administration of amylin in increasing energy expenditure has been demonstrated (Wielinga et al. 2007) . Acute administration of amylin agonist, salmon calcitonin but not amylin signifi cantly stimulated energy expenditure in fasted animals (Roth et al. 2006) .
Ghrelin is the only known orexigenic gut peptide secreted mainly from the stomach. Th e pre-prandial elevation of ghrelin levels and its fall aft er meals led to the notion that ghrelin is a 'hunger' hormone responsible for meal initiation. Ghrelin is involved in short-term regulation of the food intake and longterm regulation of bodyweight through decreasing fat utilization (Castaneda et al. 2010) . Th e eff ect of ghrelin on food intake is mediated through the growth hormone secretagogue receptor 1a (GHS-R1a), which is highly expressed in the hypothalamic cell populations that regulate the feeding and the body weight homeostasis. Th is was evidenced by lack of the orexigenic eff ect of ghrelin in GHS-R knocked out mice ). Ghrelin's orexigenic eff ect is mediated by specifi c modulation of AgRP/NPY neurons in the ARC without demonstrated change in the mRNA levels of the other feeding-promoting neuropeptides such as melanocyte stimulating hormone (MCH) and pre-pro-orexin (OX) (Cowley et al. 2003) . Recent data have indicated that the orexigenic eff ect of ghrelin is mediated by its modulation of the hypothalamic adenosine monophosphate (AMP)-activated protein kinase (AMPK) enzyme activity (Kola et al. 2008) . Th e detection of the ghrelin receptors on the vagal afferent neurons in the rat suggests that ghrelin signals from the stomach are transmitted to the brain via the vagus nerve (Date 2012) . However, the fi ndings regarding eff ect of vagatomy on the orexigenic eff ect of ghrelin in animal models and humans is not universal. Th e vagal aff erents cut was not necessary for the orexigenic eff ect of the peripherally injected ghrelin in rats (Arnold et al. 2006) as well as gastrectomy in humans accompanied by vagatomy did not prevent the orexigenic eff ects of ghrelin treatment, indicating that intact vagus is not required for its orexigenic effects (Adachi et al. 2010) . Th e orexigenic and lipogenic eff ect of ghrelin provide a potential use of ghrelin antagonists or reverse agonists in the treatment of the obesity (Alvarez-Castro et al. 2013) . However, studies in this area have shown confl icting results (Costantini et al. 2011; Abdel-Hakim et al. 2014 ).
Role of peripheral adiposity signals
Adiposity signals are signals that inform the brain about the mass of the adipose tissue. Basal levels of insulin and leptin are widely accepted to be adiposity signals. Amylin, ghrelin, and peptide YY have been hypothesized to be adiposity signals (reviewed by Hillebrand and Geary 2010) .
Leptin is a peptide hormone produced by the ob gene and secreted mainly by the adipose tissue, playing a key role in the energy homeostasis (Klok et al. 2007) . Th e production of leptin is higher in the subcutaneous than in visceral fat, and its level in the blood correlate directly with the amount of body fat. Th e secretion of leptin is reduced during periods of fasting and increased aft er meals. It is infl uenced by several metabolic and hormonal factors (Friedman 2004) .
Leptin is transported across the BBB by a saturable system and exerts its anorectic eff ect in the ARC via inhibition of NPY/AgRP neurons and activation of POMC/ CART neurons resulting in reduced food intake and increased energy expenditure. Th e Ob-Rb receptor, which is highly expressed in the hypothalamus, is thought to be the main receptor involved in the appetite regulation. Ob-Rb receptor belongs to the type I cytokine receptor family and exists in fi ve distinct isoforms (splice variants) named as Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd, and Ob-Re. Only the Ob-Rb isoform contains a long intracellular domain essential for the biological actions of leptin (Suzuki et al. 2010) .
Human obesity is generally associated with high serum levels of leptin and less effi cient transport across the BBB, consistent with a state of central resistance to leptin. Th is resistance may be secondary to obesity or vice versa, and genetic factors, age, diet, sedentary lifestyle, and stress might contribute to the development of defects in the transport of leptin across the BBB or might lead to abnormalities in leptin signaling (Paz-Filho et al. 2009 ).
Adiponectin and resistin. Th e adipose tissue produces numerous other factors that may directly or indirectly infl uence the energy balance and body weight. Adiponectin is one of these factors. Th e physiological eff ect of adiponectin is to increase energy expenditure and to protect against insulin resistance and atherosclerosis (Trujillo and Scherer 2006) . Studies have shown that adiponectin activates signal transduction pathways similar to leptin and insulin in the hypothalamus, reinforcing its role in the central control of energy homeostasis (Coope et al. 2008) . In humans, serum adiponectin levels are inversely related to adiposity and insulin resistance, increasing aft er weight loss induced by diet or bariatric surgery (Ahima and Lazar 2008) . In contrast, resistin is a peptide produced by adipocytes and increases insulin resistance via paracrine actions. Serum levels of resistin are increased in obesity (Banerjee et al. 2004) .
Other adipocytokines involved in energy balance. Tumor necrosis factor-α is correlated with the amount of body fat, inhibits feeding, increases metabolic rate, and induces cachexia (Galic et al. 2010) . Another potential adipocytokine involved in energy homeostasis is interleukin-6 (IL-6). Several data have suggested a potential protective role of IL-6 against the development of obesity (Wallenius et al. 2003) . However, the data are not consistent between diff erent research groups and the actual involvement of IL-6 in controlling the energy balance requires additional studies (Ahima and Lazar 2008) . In addition, it has been demonstrated that atrial natriuretic peptide (ANP) is expressed and secreted by human preadipocytes. ANP is not only a strong hypotensive, but also a lipolytic compound (Garruti et al. 2008 ).
Role of catecholamines
Norepinephrine (NE), synthesized in both the central and peripheral nervous system, is involved in food intake regulation of both mammals and chickens. NPY, a potent orexigenic peptide, is co-localized with NE in the central and peripheral nervous system, suggesting an interaction (Katayama et al. 2010) . Th e eff ect of NE on the food intake is a point of great controversy. Some studies have demonstrated an increase in the food intake following central NE injection in the anterior and medial hypothalamus, and explained the increase in feeding following ovariectomy by increase in NE (Simpson and Dicara 1973) . In contrast, several studies have demonstrated a dosedependent decrease in food intake following ICV injection of NE in rats and chickens (Katayama et al. 2010) . Another study evidenced that noradrenergic neurons in the area postrema mediate at least part of the hypophagic action of amylin (Potes et al. 2010) .
In the lateral hypothalamus (LH), Leibowitz (1978) has found that epinephrine, NE or dopamine had an anti-feeding eff ect. Beta-adrenergic or dopaminergic drugs injected into the LH tend to inhibit feeding. Similarly, drugs that release catecholamines also inhibit feeding (Hoebel 1985) . Several studies have Abbreviations: ACTH -adrenocorticotropic hormone; NPY -neuropeptide Y; AgRP -agouti related peptide; CRH -corticotrophin releasing hormone; TRH -thyroid releasing hormone; POMC -pro-opiomelanocortin; CART -cocaine-amphetamine regulated transcript; CCK -cholecystokinin; MCH -melanin-concentrating hormone; PYY -peptide tyrosine tyrosine; PPpancreatic polypeptide; GALPn -galanin-like peptide; GLP-1 -glucagon-like peptide 1; BDNF -brain derived neurotrophic factor; α-MSH -alpha melanocyte stimulating hormone suggested that the anorexic action of amphetamine is mediated by releasing of catecholamines in LH (Leibowitz 1978) and so amphetamine loses its eff ect aft er killing the catechobamine terminals in the LH with 6-hydroxydopamine. Without these LH catecholamines the animal a) overeats; b) self-stimulates faster; c) becomes moderately obese, d) is less responsive to amphetamine treatment (Hoebel 1985) . In the medial hypothalamus (MH), NE input does the opposite. It inhibits the satiety. In front of the MH, the PVN, which lies along the sides of the third ventricle, is the most sensitive site for eff ect of NE on feeding where injection of NE or NE mimetics will initiate and also prolong the meal. Amphetamine-induced feeding may sound paradoxically, but it is easily observed and explained when the amphetamine is applied locally into the PVN, where it could inhibit satiety (Leibowitz 1978) . Summary of central as well as peripheral orexigenic and anorexigenic hormones/ peptides are shown in Table 1 .
Conclusion
Food intake is controlled centrally by the hypothalamus, brainstem, reward system, and endocannabinoids. Th e peripheral control of the food intake includes signals from the gastrointestinal tract and adipose tissue. Th e GIT hormones aff ecting food intake include ghrelin, an orexigenic peptide that act to increase food intake and anorexigenic hormones that act to decrease food intake and leads to satiation. Th e agonists for the anorexigenic and antagonist for the orexigenic peptides have been investigated in the treatment of obesity.
